New hope for Tough-to-Treat leukemias: experimental drug enters human trials
NCT ID NCT04581512
Summary
This early-stage study is testing a new oral drug called EP0042, both alone and combined with other cancer treatments, in adults with advanced blood cancers like acute myeloid leukemia (AML). The main goal is to find a safe and tolerable dose. The study is for patients whose cancer has returned or hasn't responded to previous treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Amsterdam UMC
RECRUITINGAmsterdam, Amsterdam, 1081HV Amsterdam, Netherlands
Contact Email: •••••@•••••
-
Erasmus MC
RECRUITINGRotterdam, Rotterdam, 3000 CA Rotterdam, Netherlands
Contact Email: •••••@•••••
-
Royal Perth Hospital
RECRUITINGPerth, Western Australia, 6000, Australia
Contact Email: •••••@•••••
-
The Christie Hospital
RECRUITINGManchester, M204BX, United Kingdom
Contact Email: •••••@•••••
-
The Royal Marsden
RECRUITINGLondon, UK, United Kingdom
Contact Email: •••••@•••••
Contact
-
University College London Hospital
RECRUITINGLondon, London, W1T 7HA, United Kingdom
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.